...development, and named Adam Thomas chief human resources officer. Gengos was president and CEO of ImmunoCellular Therapeutics Ltd....

...is unable at this time to secure sufficient additional financial resources to complete the trial. ImmunoCellular...
...unmethylated O6-methylguanine-DNA methyltransferase (MGMT) tumors and with methylated MGMT tumors, progression-free survival (PFS) and safety. ImmunoCellular...
...the trial. ICT-107 is an intradermal dendritic cell-based therapeutic vaccine that targets 6 tumor-associated antigens. ImmunoCellular Therapeutics Ltd....

...NYSE:GSK) Demcizumab failed two Ph II trials, analysis ongoing; tarextumab discontinued after failing Ph II ImmunoCellular Therapeutics Ltd....
...reflects on cancer stem cells more broadly,” he told BioCentury. And while Verastem Inc. and ImmunoCellular Therapeutics Ltd....
...AG (Xetra:BAYN), Leverkusen, Germany Celgene Corp. (NASDAQ:CELG), Summit, N.J. Genentech Inc., South San Francisco, Calif. ImmunoCellular Therapeutics Ltd....

...testing tumor-associated DC-based vaccines to prevent metastasis and tumor relapse in mouse models of cancer. ImmunoCellular Therapeutics Ltd....

...NASDAQ:ACAD) 8/9/16 $230.0 $3,992.2 $3,848.2 -4% BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) 8/9/16 $720.0 $16,412.7 $15,817.8 -4% ImmunoCellular Therapeutics Ltd....

...Price: $0.16 Shares after offering: 127.8 million Underwriters: Maxim Group; Laidlaw Overallotment: 7.1 million Note: ImmunoCellular...

...weeks followed by maintenance treatment every 2 months until vaccine supply depletion or progressive disease. ImmunoCellular Therapeutics Ltd....

...million Shares: 51.5 million Price prior: $0.27 Underwriters: Maxim Group; Laidlaw Overallotment: 7.7 million Note: ImmunoCellular...

...million Shares: 60 million Price Prior: $0.27 Underwriters: Maxim Group; Laidlaw Overallotment: 9 million Note: ImmunoCellular...

...and every 6 months thereafter. The company has an SPA from FDA for the trial. ImmunoCellular Therapeutics Ltd....